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ABSTRACT 
  
 In the United States, metastatic breast cancer kills approximately 40,000 women 
and 400 men annually, and approximately 200,000 new cases of breast cancer are 
diagnosed each year.  Worldwide, breast cancer is the leading cause of cancer deaths 
among women.  Despite advances in the detection and treatment of metastatic breast 
cancer, mortality rates from this disease remain high because the fact is that once 
metastatic, it is virtually incurable.  It is widely accepted that a major reason breast 
cancer continues to exhibit recurrence after remission is that current therapies are 
insufficient for targeting and eliminating therapy-resistant cancer cells.  Emerging 
research has demonstrated that these therapy-resistant cells possess stem cell-like 
properties and are therefore commonly referred to as breast cancer stem cells (BCSCs).  
A major hallmark of BCSCs is the cell surface expression of CD44 and lack of 
expression of CD24, the so-called CD24-/CD44+ phenotype.  Research indicates that this 
dangerous and rare subpopulation of BCSCs may be responsible for cancer onset, 
recurrence, and ultimately metastasis that leads to death. 
 
 Two different model systems were utilized in this research.  The first was the 
MCF7 cell line, a luminal A tumor subtype representative of a mildly invasive breast 
ductal carcinoma with an ER+/PR+/-/HER2- immunoprofile.  The second was the 
MCF10A breast cancer progression model, which consists of three cell lines: MCF10A, 
MCF10AT1, and MCF10CA1a.  In this system, spontaneously immortalized, non-
malignant MCF10A cells were transfected with constitutively active H-Ras to form pre-
malignant MCF10AT1 cells, which were then subcutaneously injected into mice and 
allowed to metastasize in order to form the oncogenic MCF10ACA1a cell line. 
 
 This thesis presents evidence of a CD24low/-/CD44+ BCSC subpopulation within 
the MCF10A breast cancer progression model system.  Findings indicate that RUNX1 
and RUNX2 expression levels are involved in maintaining the BCSC phenotype.  Across 
two different model systems, qRT-PCR analysis revealed that decreased levels of 
RUNX1 expression and increased levels of RUNX2 expression are essential for the 
maintenance of the BCSC subpopulation.  It was also shown that low expression levels of 
RUNX1 and high expression levels of RUNX2 are present in CD24low/-/CD44+ BCSCs as 
compared to CD24+/CD44+ non-BCSCs.  Furthermore, shRNA knockdown of RUNX1 
was shown to enhance tumorigenicity, while shRNA knockdown of RUNX2 repressed 
tumorigenicity in BCSCs, as measured by the tumorsphere-formation assay.  This 
research lays the groundwork for future investigations into the roles of RUNX1 and 








 I wish to take this opportunity to express my most sincere gratitude to my 
mentor, Dr. Gary Stein, who supported me throughout the course of my 
graduate studies.  I would like to give special thanks to Dr. Janet Stein who 
provided me guidance and constant encouragement during my time as a 
graduate student.  I also wish to thank all members of the Stein-Lian Laboratory, 
both past and present, who consistently provided me with invaluable insight and 
mentorship at the bench. 
 I would like to thank the members of my thesis committee, Dr. David 
Pederson and Dr. Seth Frietze, for providing me with guidance throughout the 
course of my research.  I am deeply grateful to the Cellular, Molecular and 
Biomedical Sciences Graduate Program for providing me with the opportunities 
both to pursue an exciting and rewarding research project, and to gain 
experience teaching.  Special thanks to Dr. Matthew Poynter and Stephanie 
Phelps for their invaluable support. 
 Finally, my success as a graduate student would not have been possible 
without the unconditional love and support of those closest to me.  Thank you 










TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ........................................................................................... ii 
 
LIST OF FIGURES ........................................................................................................ v 
 
CHAPTER 1:  LITERATURE SUMMARY .................................................................. 1 
 Cancer Stem Cells ................................................................................................... 1 
 Breast Cancer Stem Cells ........................................................................................ 2 
The MCF7 Cell Line and the MCF10A/AT1/CA1a Breast Cancer  
 Progression Model ............................................................................................ 5 
 The RUNX Family of Proteins ............................................................................... 6 
      The RUNX Genes and Cancer  .............................................................................. 7 
 
CHAPTER 2: INVESTIGATING THE ROLE OF RUNX1 IN MCF7 BREAST  
 CANCER STEM CELLS ......................................................................................... 9 
 Summary ................................................................................................................. 9 
      Introduction ............................................................................................................ 9 
 Materials and Methods ........................................................................................ 10 
Cell Culture ..................................................................................................... 10 
  Tumorsphere Culture ..................................................................................... 11 
  Quantitative Real-Time PCR .......................................................................... 11 
  Statistical Analysis .......................................................................................... 12 
 Results.................................................................................................................... 12 
  MCF7 Tumorsphere Assay ............................................................................ 12 
  Gene Expression Analysis of Adherent MCF7 Cells vs. 3-D Tumorsphere  
   Culture ....................................................................................................... 13 
  Tumorsphere Forming Efficiency of RUNX1-Depleted MCF7 Cells .......... 18 
 Discussion ............................................................................................................. 20 
 
CHAPTER 3: INVESTIGATING THE ROLE OF RUNX1 AND RUNX2 IN THE  
 MAINTENANCE OF THE CANCER STEM CELL PHENOTYPE IN A  
 BREAST CANCER PROGRESSION MODEL .................................................... 22 
 Summary ............................................................................................................... 22 
      Introduction .......................................................................................................... 22 
 Materials and Methods ........................................................................................ 24 
Cell Culture ..................................................................................................... 24 
  Mammosphere and Tumorsphere Culture ................................................... 24 
  CD24/CD44 Flow Cytometry ........................................................................ 25 
  Quantitative Real-Time PCR .......................................................................... 26 
  West Blotting ................................................................................................... 26 
  Statistical Analysis .......................................................................................... 28 
iv		
 Results.................................................................................................................... 28 
  Identification and Isolation of Breast Cancer Stem Cells ............................ 28 
  MCF10A/AT1/CA1a Mammosphere/Tumorsphere Assay ...................... 30 
  Tumorsphere Forming Capacity of MCF10AT1 Subpopulations ............... 33 
  RNA and Protein Expression Analysis of MCF10AT1  
            CD24low/-/CD44+ BCSCs vs. CD24+/CD44+ non-BCSCs. ............................ 36 
  CD24/CD44 Flow Cytometric Analysis and Tumorsphere Forming  
   Efficiency of MCF10AT1 shRUNX2 Knockdown Cells ......................... 41 
 Discussion ............................................................................................................. 44 
 
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS............................... 45 
 Summary ............................................................................................................... 45 
 Implications and Future Directions  ................................................................... 45 
 






LIST OF FIGURES 
 
Figure 1. MCF7 Tumorsphere Assay ........................................................................ 16 	
Figure 2. Gene Expression Analysis of Adherent MCF7 cells vs.  
 MCF7 Tumorspheres. ........................................................................................... 17 	
Figure 3. Analysis of Tumorsphere Forming Efficiency in MCF7 Parental 
  Cells vs. RUNX1 Knockdown. ............................................................................. 19 
 
Figure 4. FACS Gating Strategy for MCF10AT1 CD24low/-/CD44+ BCSC and  
 CD24+/CD44+ non-BCSC Populations ............................................................... 29 
 
Figure 5. MCF10A, MCF10AT1 and MCF10CA1a 
 Mammosphere/Tumorsphere Assays ................................................................ 32 
 
Figure 6. MCF10AT1 CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC  
 Tumorsphere Assays ............................................................................................ 34 
 
Figure 7. Analysis of Tumorsphere Forming Efficiency in MCF10AT1 
 CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC  
 Tumorsphere Assays ............................................................................................ 35 
 
Figure 8. Gene Expression Analysis of MCF10AT1 CD24low/-/CD44+  
 BCSCs vs. CD24+/CD44+ non-BCSCs. ................................................................ 38 
 
Figure 9. Western Blots and Protein Quantification of RUNX1, RUNX2,  
 Zeb1, Vimentin and CD24 in MCF10AT1 CD24low/-/CD44+ BCSCs vs.  
 CD24+/CD44+ non-BCSCs. .................................................................................. 40 
 
Figure 10. CD24/CD44 Flow Cytometry of MCF10AT1 shRUNX2 
 Knockdown Cells vs. Parental and Empty Vector Control ............................... 42 
 
Figure 11. Tumorsphere Assays and TFE Analysis of MCF10AT1 shRUNX2  




CHAPTER 1: LITERATURE SUMMARY 
 
Cancer Stem Cells 
 The existence of cancer stem cells first came to light back in the 1960’s and 
1970’s when researchers studying leukemia and myeloma discovered that only a 
sub-fraction of cancer cells possessed the ability to proliferate extensively [1, 2].  
Over the course of the past fifteen years or so, cancer stem cells have been 
shown to exist in many different types of solid tumors, including those of the 
prostate, brain, skin, colon and breast [3–8].  The cancer stem cell theory posits 
that only a subpopulation of cells within tumors, which have stem cell-like 
properties, are capable of tumorigenesis.  These cells are defined by their ability 
to self-renew, give rise to differentiated progeny that constitute the bulk of the 
tumor mass, and form tumors in immunocompromised mice [9, 10].  This theory 
is in contrast to the traditional, stochastic model of tumorigenesis, which states 
that all cells within a tumor have tumorigenic potential [11].  It is also known 
that cancer stem cells are highly resistant to radiation and chemotherapy, and 
have enhanced metastatic potential [12, 13].  In summary, the cancer stem cell 
theory posits that only a small subpopulation of cancer cells with stem cell-like 
properties are able to self-renew and sustain a tumor, similar to the way in 
which adult stem cells self-renew and sustain tissues and organs.  In this theory, 
non-stem cancer cells are able to cause problems in the body, but it is the cancer 
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stem cell subpopulation that is responsible for the sustained longevity of the 
cancer.   
 There is still debate as to the origin of cancer stem cells.  One school of 
thought suggests that they originate from mutations in adult stem cells, while 
other possible explanations point to mutations in progenitor cells and transit 
amplifying cells as being the causative factor of their derivation.  There is also 
speculation that cancer stem cells may arise from mutations in fully 
differentiated cells that reactivate pathways governing stemness and 
transformation [17-22].  Furthermore, it has been shown that cellular signaling 
pathways governing the epithelial to mesenchymal transition (EMT) are 
involved in the maintenance of the cancer stem cell phenotype [23].  Indeed, it 
seems possible that cancer cells with stem cell-like characteristics may have more 
than one method of origin, and it is imperative to identify regulatory molecules 
responsible for maintaining the cancer stem cell phenotype so that future 
therapies can target and eliminate this dangerous subpopulation of cells in order 
to improve patient outcomes. 
Breast Cancer Stem Cells 
 In the US, metastatic breast cancer kills approximately 40,000 women and 
400 men annually, and approximately 200,000 new cases of breast cancer are 
diagnosed each year.  Worldwide, breast cancer is the leading cause of cancer 
deaths among women [24].  Despite advances in the detection and treatment of 
metastatic breast cancer, mortality rates from this disease remain high because 
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current therapies are insufficient at targeting and eliminating therapy-resistant 
breast cancer stem cells (BCSCs).  A prevailing theory in the field of breast cancer 
research ascertains that one of the main reasons cancers exhibit recurrence after 
remission is the existence BCSCs that are chemotherapy and radiotherapy 
resistant.  The resistance that BCSCs have to radiation is attributed to the ability 
of these cells to transition into and out of a quiescent state, while the 
chemoresistance of BCSCs is related to their expression of ATP-binding cassette 
(ABC) transporters, detoxifying transport pumps that normally function to 
protect cells from environmental toxins.  These transporters are up-regulated in 
BCSCs, and two in particular have been studied extensively: breast cancer 
resistance protein (ABCG2) and P-glycoprotein (MDR1).  ABCG2  is known to 
efflux doxorubicin, and MDR1 is known to efflux drugs such as paclitaxel.  It is 
the elevated expression of these types of transporters, compared to non-BCSCs, 
which gives BCSCs enhanced chemoresistance [12,13]. 
 BCSCs are characterized on the basis of three distinct abilities: self-
renewal, differentiation (the ability to form multiple lineages with non-stem cell 
characteristics), and formation of tumors in immunocompromised mice [14].  
There is still a good deal of controversy surrounding the definition of a breast 
cancer stem cell, and which biomarkers definitively identify this subpopulation 
of cells.  A lack of correlation exists with respect to the biomarkers used to 
identify and define BCSCs among different breast cancer cell lines and patient 
tumor samples.  Some of the most common biomarkers used to identify BCSCs 
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are the cluster of differentiation 24/44 (CD24-/CD44+) signature, aldehyde 
dehydrogenase 1A1 (ALDH+), and SRY-box 2 (Sox2+).  It is speculated that each 
of these populations represents a unique subpopulation of breast cancer cells 
with stem cell-like properties rather than one common and definitive BCSC 
population [25].  One of the most common methods used for studying BCSCs is 
isolation of the CD24-/CD44+ fraction by fluorescence activated cell sorting 
(FACS). 
 A major way in which self-renewal ability and tumorigenicity is assessed 
in the BCSC population is by subjecting BCSCs to the tumorsphere/ 
mammosphere assay.  In this assay, single isolated CD24-/CD44+ BCSCs, or 
subpopulations defined by other common biomarkers, are plated on ultra low-
attachment surfaces in serum-free medium supplemented with growth factors.  
Cells that possess a stem cell-like phenotype will proliferate and form three-
dimensional, spherical colonies in suspension called tumorspheres.  Cells that 
lack a stem cell-like phenotype will quickly die from anoikis [26].  It is believed 
that three-dimensional cell culture systems, such as mammosphere/ 
tumorsphere culture, serve as a more representative model of the in vivo cancer 
environment than two-dimensional monolayer culture [27].  Furthermore, there 
is a known association between the ability of breast cancer cells to form 
tumorsphere in vitro and the in vivo tumorigenicity of tumorsphere-derived cells.  
In one such study, Grimshaw et al. isolated metastatic cells from pleural effusions 
of breast cancer patients, and subsequently placed them in tumorsphere culture. 
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They then dissociated the tumorspheres and injected the tumorsphere-derived 
cells into SCID mice. They found that cells that formed the largest tumorspheres 
in vitro were also the most tumorigenic when xenografted into 
immunocompromised mice [28,29]. 
 Indeed, it is well known that tumorigenicity and differentiation ability can 
be assessed by injecting isolated BCSCs subcutaneously in the mammary fat pad 
of immunocompromised mice and observing the formation of primary tumors 
containing both a BCSC population and a differentiated multi-lineage 
population.  The highly tumorigenic CD24-/CD44+ phenotype of BCSCs was 
revealed in xenograft experiments conducted by the Wicha Laboratory at the 
University of Michigan, where they showed that as few as twenty cells with 
BCSC markers were required to generate primary heterogeneous tumors, 
whereas anywhere from tens of thousands up to one million non-BCSC cells 
were needed to generate primary tumors [14, 15].   
The MCF7 Cell Line and the MCF10A/AT1 /CA1a  
Breast Cancer Progression Model 
 The MCF7 cell line is one of the most widely used model systems in breast 
cancer research.  It originated from a pleural effusion of a 69-year-old Caucasian 
woman.  These cells have a luminal epithelial mammary gland phenotype, and 
represent a luminal A tumor subtype.  It is a mildly invasive breast ductal 
carcinoma, and has an ER+/PR+/-/HER2- immunoprofile.  This cell line has been 
used widely for over forty years, and there has been extensive research done on 
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its molecular profile, invasion, migration and proliferation characteristics, and its 
involvement in lymphangiogenesis and angiogenesis [30,31].  More recently, it 
has been shown that that MCF7 cells have the ability to form tumorspheres when 
cultured in serum-free medium in non-adherent conditions. [32] 
 The MCF10A breast cancer progression model consists of three cell lines: 
MCF10A, MCF10AT1, and MCF10CA1a.  The MCF10A cells are non-malignant 
breast cells, derived from a patient with benign fibrocystic disease, that were 
spontaneously immortalized.  These cells are not capable of forming tumors [33].  
MCF10A cells were transfected with constitutively active H-Ras to form the pre-
malignant MCF10AT1 cell line, which is able to form tumors in xenograft 
experiments with a 25% incidence [34].  MCF10AT1 cells were then 
subcutaneously injected into mice and allowed to metastasize in order to form 
the oncogenic MCF10ACA1a cell line, which contains a PIK3CA H1047R 
activating mutation.  These cells always result in tumor formation when injected 
subcutaneously into immunocompromised mice [35].  This model system is 
widely used to study breast cancer progression. 
The RUNX Family of Proteins 
 The RUNX (runt-related transcription factor) family of proteins is a group 
of evolutionarily conserved transcription factors that are involved in the 
regulation of developmental processes.  Mammals have three RUNX genes: 
RUNX1, RUNX2 and RUNX3, and their expression and function vary based on 
tissue type.  RUNX genes are involved in many major pathways associated with 
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development, such as WNT3, Notch5, transforming growth factor-β (TGFβ ), 
YAP1, and Indian hedgehog4.  All three of the RUNX genes in mammals are 
regulated by dual promoters, which are activated at different times during 
development to create distinct RUNX isoforms.  Isoforms of the RUNX genes, 
which have distinctive properties, are also formed via alternative splicing events. 
The Runt domain, a highly conserved DNA-binding domain that contains both 
activation and inhibitory domains, is present in each of the RUNX proteins, and 
it binds to CBFβ in order to stabilize the interaction of RUNX with the DNA.  The 
RUNX proteins are not strong transcriptional regulators by themselves, but their 
interactions with other proteins, such as such as H3K4 methyltransferase mixed-
lineage leukaemia (MLL ), histone deacetylases (HDACs), and Polycomb 
repressive complex 1 (PRC1), enhances their transcriptional activity [36-38]. 
The RUNX Genes and Cancer 
Mutations in the RUNX genes are associated with a variety of cancers.  
Mutations in RUNX1, also known as acute myeloid leukemia 1 protein (AML1), 
play a significant role in leukemogenesis.  RUNX2 is involved in bone 
development and differentiation. It is a factor specific to the bone lineage, and it 
is known to play a role in osteosarcoma.  Elevated levels of RUNX2 are 
associated with bone-metastatic breast and prostate cancer, whereas inactivation 
of RUNX3 is a hallmark of many solid tumors [39–42].  The role that the RUNX 
genes play in the development of cancer was greatly elucidated when it was 
discovered that they are MYC-collaborating genes.  All of the RUNX genes were 
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identified as viral insertional targets via proviral insertional mutagenesis 
experiments in mice genetically engineered to exhibit MYC-overexpression in T-
lymphocytes (CD2–Myc transgenic mice).  It has also been shown that viral-
induced overexpression of RUNX proteins can result in aggressive T-cell 
lymphomas, and retroviral insertional mutation screens in Arf-knockout mice 
have revealed a link between RUNX and p53 in both lymphomagenesis and 
leukaemogenesis. [43-46].  Previous work from our lab using the MMTV-PyMT 
transgenic mouse model of breast cancer confirmed that RUNX1 is associated 
with breast cancer progression, and depletion of RUNX1 resulted in the 
inhibition of breast cancer invasion and migration.  In this study, high levels of 
RUNX1 expression were found in MMTV-derived tumor cells, as well as in lung-
metastatic legions of MMTV-PyMT mice.  The ultimate conclusion drawn from 
this work was that breast cancer progression and metastasis is strongly linked to 
the dysregulation of RUNX1 in tumor epithelial cells [47].  Furthermore, 
previous studies from our group have repeatedly shown that RUNX2 is involved 
in breast cancer metastasis, predominantly to bone. [40,48,49].  Lastly, RUNX1 
has been shown to be necessary for the development of mammary stem cells [50], 
which lead us to speculate about its role in breast cancer stem cells, and recent 
work done by our group has revealed that RUNX1 can function as a tumor 
suppressor by inhibiting the EMT process and promoting the maintenance of the 
epithelial phenotype [51]. 
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CHAPTER 2: INVESTIGATING THE ROLE OF RUNX1  
IN MCF7 BREAST CANCER STEM CELLS 
Summary 
 The focus of this chapter is an analysis of a putative breast cancer stem cell 
population within a well-known and extensively researched model system of 
luminal breast cancer.  It was hypothesized that since RUNX1 is known to have 
tumor suppressor activity, and is also known to be involved in the development 
of normal mammary stem cells, that depletion of the RUNX1 gene in MCF7 cells 
would promote the breast cancer stem cell phenotype.  An experimental 
technique, the tumorsphere assay, was established for the first time in our 
laboratory in order to investigate this hypothesis.  In this body of work, we show 
successful generation of tumorspheres, from the MCF7 cell line, that have 
increased expression of genes known to be associated with the breast cancer stem 
cell phenotype.  We also show that when RUNX1 is depleted in this model 
system by an shRNA approach, tumorsphere formation, an indicator of 
tumorigenic potential, is increased; this outcome lends support to the role of 
RUNX1 as a tumor suppressor. 
 
Introduction 
 Tumorspheres are single cell-derived, three-dimensional spherical 
colonies that grow in suspension when seeded into serum-free medium in ultra 
low-attachment plates.  Tumorsphere culture is an established method used to 
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enrich for BCSCs, which is evidenced by the fact that tumorsphere forming 
ability of breast cancer cells in vitro correlates with the ability of tumorsphere 
cells to form tumors in immunocompromised mice in vivo [28,29].  Additionally, 
it is known that RUNX1 is involved in the development of normal mammary 
stem cells [50], and previous work by our group and others has shown that 
RUNX1 is involved in breast cancer progression [47].  Taken together, this 
evidence led us to hypothesize that RUNX1 may be involved in the 
establishment or maintenance of the BCSC population.  In the experiments 
outlined in this chapter, we set out to utilize tumorsphere culture of the MCF7 
cell line, a well known, established cell line capable of tumorsphere formation 
[30-32], as a means to enrich for BCSCs in order to begin investigating the 
putative role of RUNX1 in the BSCS phenotype. 
 
Materials and Methods 
Cell Culture 
 MCF7 cells were cultured in 100 mm plates in Dulbecco’s Modified Eagle 
Medium/Ham’s F-12 50/50 (Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, 
Flowery Branch, GA, USA) and 1% (v/v) 50 IU/ml penicillin/50 µg/ml 
streptomycin (Life Technologies, Carlsbad, CA, USA).  Cells were passaged 
every three to four days with 0.05% trypsin-EDTA, and media was replenished 
every other day. 
11		
Tumorsphere Culture 
 Adherent MCF7 cells were grown to 70 – 80% confluence and 
enzymatically dissociated into a single-cell suspension with 0.05% trypsin-EDTA.  
For tumorsphere formation assays, single cells were seeded into 6-well ultra-low 
attachment plates (Corning, Corning, NY, USA) at a density of either 8,000 or 
16,000 cells per well and maintained in Mammocult Medium (STEMCELL 
Technologies, Vancouver, British Columbia, Canada) for four to five days.  For 
qRT-PCR analysis, cells were seeded at a density of 1 x106 cells per plate in 100 
mm Petri dishes, for the same duration of time, in order to obtain enough 
material for analysis.  Tumorsphere formation efficiency (TFE) was calculated by 
dividing the number of tumorspheres formed by the number of single cells 
seeded, expressed as a percentage.  Tumorspheres were manually counted under 
100X magnification using an inverted phase-contrast microscope (Leica 
Microsystems, Wetzlar, DE).   
Quantitative Real-Time PCR 
 Adherent MCF7 cell cultures that were approximately 70-80% confluent 
and Day 4-5 tumorsphere cultures were collected in Trizol (Life Technologies).  
RNA was isolated using the miRNeasy Mini Kit (Qiagen, Germantown, MD, 
USA).  cDNA was synthesized using the SuperScript III First-Strand Synthesis 
System for RT-PCR (Life Technologies) and subsequently diluted at a 1:15 ratio 
prior to performing quantitative real-time PCR using SYBR Green PCR Master 
Mix (Applied Biosystems Foster City, CA, USA). 
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Statistical Analysis  
 Tumorsphere formation efficiency assays were repeated at least three 
times.  The differences in mean values among groups were calculated, and TFE is 
expressed as the mean ± SEM.  qRT-PCR analyses were conducted on two 
biological replicates.  
 
Results 
MCF7 Tumorsphere Assay 
 When adherent breast cancer cells are placed into tumorsphere culture 
conditions in ultra-low attachment plates, these cells are prevented from 
attaching to a substrate and are forced to grow in suspension.  In such 
conditions, the vast majority of cells die as a result of anoikis, while those that 
have stem-like properties are able to replicate and form three-dimensional 
spheroids.  The most important aspect of tumorsphere culture is the density, and 
this must be properly optimized in order to generate robust tumorsphere 
cultures.  If the cultures are seeded at too high of a density, the tumorspheres 
will begin to fuse together, oftentimes so much so that all of the spheroids in a 
given culture well or plate will fuse into one continuous string-like structure that 
quickly becomes necrotic.  In these experiments, tumorsphere cultures were 
successfully harvested for qRT-PCR analysis.  Photomicrographs were taken 
every 24 hours for the duration of culture.  Tumorspheres at Day 4 measured 
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between 100 – 200 μm in diameter.  Images shown are representative of at least 
three biological replicates (Figure 1). 
 Tumorspheres began to be observable in culture at Day 1 when they were 
typically between 20 – 50 μm in diameter.  During both Day 1 and Day 2 of 
culture, dying cells, or “ghost cells”, were observed attached to the forming 
spheroids. These are the cells that lack stem-like properties and are undergoing 
anoikis.  Once the cultures reach Day 3 and Day 4, “ghost cells” were almost non-
existent and the tumorspheres exhibited a smooth surface morphology.  It is 
important to carefully determine beforehand the day that cultures reach 
maturity, for this is when the tumorspheres need to be counted for TFE analysis.  
The appropriate time to conduct the TFE assay is before the majority of the 
tumorspheres in culture begin to exhibit dark, necrotic cores.  Once this takes 
place, the tumorspheres will continue to grow in size for several days; however, 
the necrosis begins to consume the entirety of the spheroids.  If the cultures are 
allowed to go beyond this point, the spheroids will eventually begin to break 
apart until the point where there are no observable live cells in the culture. 
Through optimization, it was determined that the point of maturity for MCF7 
tumorsphere culture was typically between Day 4 and Day 5. 
Gene Expression Analysis of Adherent MCF7 Cells vs. 3-D Tumorsphere 
Culture 
 Gene expression analysis by qRT-PCR was performed on adherent MCF7 
cells as well as whole tumorspheres that were harvested on Day 4, and results 
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were analyzed using GAPDH as a control (Figure 2).  Tumorsphere-derived cells 
showed increased expression of RUNX1 (p = 0.043), RUNX2 (p = 0.044), Oct4 (p 
= 0.036), Nanog (p = 0.0021), Sox2 (p = 0.0031) and Vimentin (p = 0.024) 
compared to adherent cells.  A very slight increase in CD44 and E-cadherin 
expression was also observed in tumorspheres compared to adherent cells, 
though this was not statistically significant, and there was no observable 
difference in CD24 expression levels between tumorspheres and adherent cells.  
This gene expression analysis was performed on two biological replicates.  Gene 
expression analysis of RUNX1 and RUNX2 levels was performed because the 
aim of this study was to gain insight into whether or not altered levels of these 
transcription factors are associated with the cancer stem cell phenotype.  Oct4, 
Nanog and Sox2 were examined because these are known markers of 
pluripotency and stemness.  Vimentin and E-cadherin were chosen because they 
are known markers of the epithelial to mesenchymal transition (EMT), and 
altered expression of EMT markers is often associated with the cancer stem cell 
phenotype.  CD24 and CD44 were examined because one known phenotype 
associated with breast cancer stem cells is CD24low/-/CD44+, however significant 
differences in these markers were not observed in adherent MCF7 cells 
compared to whole tumorspheres.  The CD24low/- fraction is a mixed population 
of cells containing low or no CD24 expression as determined by FACS analysis.   
We hypothesized that since BSCSs with this aggressive BCSC phenotype are 
known to represent only a very small fraction of total breast cancer cells, this 
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CD24low/-/CD44+ phenotype was not observable when examining whole 
















Figure 1. MCF7 Tumorsphere Assay 
MCF7 tumorsphere cultures were successfully established and maintained in 
culture for a period of four days. Representative images are shown at 100X and 
200X magnification. Tumorspheres at Day 4 measured between 100 – 200 µm.  




Figure 2. Gene Expression Analysis of Adherent MCF7 cells vs. MCF7 
Tumorspheres. 
MCF7 tumorsphere cells exhibited significantly increased expression of RUNX1, 
RUNX2, and the pluripotency markers Oct4, Nanog and Sox2, as well as 
decreased expression of Vimentin, compared to adherent cells. Differences in 
CD24, CD44 and E-Cadherin expression levels were not significant. Error bars 
represent mean ± SEM. P-values are shown where differences in expression 
levels were significant. The expression differences in CD24, CD44 and E-





Tumorsphere Forming Efficiency of RUNX1-Depleted MCF7 Cells 
 To gain further insight into whether or not RUNX1 plays a role in the 
breast cancer stem cell phenotype, we used a RUNX1-knockdown MCF7 cell line 
previously created in our lab by Deli Hong [51].  We compared the tumorsphere 
forming efficiency (TFE) across MCF7 parental cells, two shRNA knockdown 
MCF7 stable cell lines representing two different shRNA constructs (C1 and C4), 
as well as a non-silencing shRNA control (NS) (Figure 3).  TFE values were as 
follows: Parental = 1.25 ± 0.05% SEM, NS control = 1.17 ± 0.04% SEM, shRUNX1 
C1 = 1.85 ± 0.03% SEM, and shRUNX1 C4 = 2.12 ± 0.05% SEM.  These results 
show that knockdown of RUNX1 in MCF7 cells resulted in increased 
tumorsphere-forming ability compared to the non-silencing control. This 
indicated that shRUNX1-depleted MCF7 cells have increased tumorigenic 
potential, lending support to the notion that RUNX1 has tumor suppressor 
activity, and providing evidence that knockdown of RUNX1 may promote 











Figure 3. Analysis of Tumorsphere Forming Efficiency in MCF7 Parental Cells vs. 
RUNX1 Knockdown. 
shRUNX1 MCF7 cells exhibited an approximately 2-fold greater tumorsphere 
forming ability compared with the non-silencing control.  Results shown are 




These experiments represented our first investigations into the cancer 
stem cell phenotype, as we set out to establish breast cancer stem cell research 
protocols.  Through lengthy optimization and troubleshooting, we were able to 
successfully establish tumorsphere cultures from the MCF7 cell line.  We showed 
that tumorspheres, a known measure of tumorigenic potential and cancer 
stemness, created from this model system express genes shown to be essential for 
pluripotency and known to be associated with the breast cancer stem cell 
phenotype.  Our results also showed that tumorsphere-derived breast cancer 
stem cells exhibited increased expression of RUNX1 and RUNX2 compared to 
adherent cells.  Furthermore, our results revealed that both shRUNX1 MCF7 cell 
lines exhibited increased tumorsphere-forming ability (~2-fold) compared with 
the non-silencing control.  This indicated that knockdown of RUNX1 increased 
tumorigenic potential; lending support to the notion that RUNX1 exhibits tumor 
suppressor activity. 
 Interestingly, although loss of RUNX1 increased tumorsphere forming 
efficiency, the tumorsphere population as a whole exhibited higher RUNX1 
expression levels than adherent MCF7 cells.  This observation suggested that 
perhaps there is a subpopulation of cells within tumorspheres that express high 
levels of RUNX1 that may potentially represent breast cancer stem cells with 
significantly enhanced tumorigenic potential. 
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  The initial rationale for this investigation strategy was to utilize 
tumorsphere culture as a means of enriching a breast cancer stem cell population 
large enough to conduct downstream analyses, since the CD24-/CD44+ fraction 
in our MCF7 cell line was incredibly scarce (~ 0.5 – 1.0% of cells).  This method 
proved to be technically unfeasible and prohibitively expensive, and thus this 
line of investigation was cut short.  As a result, some experiments did not include 
a minimum of three biological replicates.  We decided to move on to a different 
model system, which provided a much larger CD24-/CD44+ population to work 

















CHAPTER 3: INVESTIGATING THE ROLE OF RUNX1 AND RUNX2 IN THE 
MAINTENANCE OF THE CANCER STEM CELL PHENOTYPE  
IN A BREAST CANCER PROGRESSION MODEL 
Summary 
 The focus of this chapter is the identification and analysis of a putative 
breast cancer stem cell population within a known model system of breast cancer 
progression.  We were able to identify, isolate and investigate a CD24low/-/CD44+ 
breast cancer stem cell subpopulation within the pre-malignant, tumorigenic 
MCF10AT1 cell line of this progression model.  We showed that this BCSC 
subpopulation has decreased levels of RUNX1 expression and increased levels of 
RUNX2 expression compared to the non-BCSC population, lending further 
support to the putative role of RUNX1 as a tumor suppressor.  Given the fact that 
elevated levels of RUNX2 are associated with some metastatic breast cancers, 
and the fact that breast cancer stem cells are known to have increased metastatic 
potential, we hypothesized that depletion of RUNX2 by an shRNA approach 
would suppress the breast cancer stem cell phenotype.  Our results provided 
preliminary evidence that depleting RUNX2 decreased the breast cancer stem 
cell population in this model system of breast cancer progression. 
 
Introduction 
 The MCF10A model consists of three cell lines that together represent a 
complete progression system from normal, but immortalized, breast epithelial 
cells to fully metastatic breast cancer cells.  MCF10A cells were derived from 
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benign breast tissue of a female patient with fibrocystic disease.  These cells were 
subsequently transformed via transfection with T24 Ha-ras to form the 
premalignant MCF10AT1 cell line.  MCF10AT1 cells were then subcutaneously 
injected into SCID mice and allowed to metastasize in order to generate the 
metastatic MCF10CA1a cell line [34,35].   
 It has previously been established by our group that RUNX1 and RUNX2 
are intimately involved in breast cancer progression and metastasis [47-49].  
Furthermore, it is known that BCSCs are a highly aggressive and metastatic 
subpopulation of tumor cells thought to be responsible for cancer onset, 
metastasis and recurrence following remission [14,15].  Based on the outcomes of 
the experiments outlined in Chapter 1, we needed to find a way to obtain a 
greater number of BCSCs in order to further our investigations.  Since it is known 
that human BCSCs can be identified by the CD24low/-/CD44+ phenotype [16], and 
since our preliminary FACS analyses of this model system indicated that there 
may be a significant CD24low/-/CD44+  subpopulation within the MCF10AT1 cell 
line, we chose this model in order to obtain a more robust CD24low/-/CD44+ 
BCSC population with which to further investigate the putative roles of RUNX1 






Materials and Methods 
Cell Culture 
 MCF10A and MCF10AT1 cells were cultured in 100 and 150 mm plates in 
Dulbecco’s Modified Eagle Medium/Ham’s F-12 50/50 (Thermo Fisher 
Scientific) supplemented with 5% (v/v) horse serum (Thermo Fisher Scientific), 
100 ng/ml cholera toxin (Sigma Aldrich, St. Louis, MO), 10 µg/ml human insulin 
(Sigma Aldrich), 20 ng/ml recombinant hEGF (Peprotech, Rocky Hill, NJ), 0.5 
µg/ml hydrocortisone (Sigma Aldrich), and 1% (v/v) 50 IU/ml penicillin/50 
µg/ml streptomycin (Life Technologies).  MCF10CA1a cells were cultured in 100 
and 150 mm plates in Dulbecco’s Modified Eagle Medium/Ham’s F-12 50/50 
(Thermo Fisher Scientific) supplemented with 5% (v/v) horse serum (Thermo 
Fisher Scientific) and 1% (v/v) 50 IU/ml penicillin/50 µg/ml streptomycin (Life 
Technologies).  Cells were passaged every three to five days with 0.05% trypsin-
EDTA, and media was replenished every other day.  The shRUNX2 cell lines 
were created by Alexandra Ojemann, a Master’s student in the Stein-Lian 
Laboratory. 
Mammosphere and Tumorsphere Culture 
 Adherent MCF10A, MCF10AT1 and MCF10CA1a cells were grown to 70 – 
80% confluence and enzymatically dissociated into single-cell suspensions with 
0.05% trypsin-EDTA.  Mammosphere are three-dimensional spherical colonies 
formed from non-transformed mammary cells, while tumorspheres are three-
dimensional spherical colonies formed from transformed mammary cells.  For 
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mammosphere (MCF10A) and tumorsphere (MCF10AT1, MCF10CA1a) 
formation assays, single cells were seeded into 24-well ultra-low attachment 
plates (Corning) at a density of either 1,000 or 2,000 cells per well and maintained 
in Mammocult Medium (STEMCELL Technologies) for five to seven days.  
Tumorsphere formation efficiency (TFE) was calculated by dividing the number 
of tumorspheres formed by the number of single cells seeded, expressed as a 
percentage.  Tumorspheres were manually counted under 100X magnification 
using an inverted phase-contrast microscope (Leica Microsystems).   
CD24/CD44 Flow Cytometry 
 Adherent monolayer cultures of MCF10A, MCF10AT1 and MCF10CA1a 
cells were grown to 70 – 80% confluence and gently dissociated with Accutase 
(MP Biomedicals, Santa Ana, CA, USA).  Culture vessels with Accutase were 
placed at 37° C and checked every 60 seconds to minimize incubation time with 
the dissociation agent in order to preserve the integrity of the cell surface 
markers.  The Accutase was immediately neutralized with fetal bovine serum 
(Atlanta Biologicals) and the cells were subsequently washed with 1x phosphate 
buffered saline (PBS) at a concentration of 10 mM PO43-, 137 mM NaCl, and 2.7 
mM KCl .  Cells were then quickly counted on a Countess automated cell counter 
(Invitrogen/Thermo Fisher Scientific) and 1x106 cells were re-suspended in 100 
µl 1x PBS/1%FBS containing 0.64 µg of PE/Cy7 anti-human CD24 (Biolegend, 
San Diego, CA, USA, cat. # 311120) and 5µl of APC mouse anti-human CD44 (BD 
Biosciences, San Jose, CA, USA, cat. # 559942).  Equivalent amounts of matched 
26		
isotype controls, PE/Cy7 Mouse IgG2a, κ (Biolegend, cat. # 400232) and APC 
mouse IgG2b κ (BD Biosciences, cat. # 555745), were used.  Cells were incubated 
with antibodies for thirty minutes at room temperature, washed twice with 
1xPBS/1%FBS, re-suspended in 400 µl 1xPBS/1%FBS and passed through a 40 
µm Falcon cell strainer (Thermo Fisher Scientific) in order to obtain a single-cell 
suspension. Cells were then either analyzed on a BD LSRII flow cytometer (BD 
Biosciences) or analyzed and sorted into CD24low/-/CD44+ breast cancer stem cell 
(BCSC) and CD24+/CD44+ non-BCSC fractions on a BD FACS AriaIII (BD 
Biosciences) high-speed cell sorter.  Analysis of flow cytometry data was 
performed on FlowJo software version 10.0.8rl 
Quantitative Real-Time PCR 
 CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC fractions were 
isolated via FACS and subsequently placed in Trizol (Life Technologies).  RNA 
was isolated using the miRNeasy Mini Kit (Qiagen).  cDNA was synthesized 
using the SuperScript III First-Strand Synthesis System for RT-PCR (Life 
Technologies) and subsequently diluted at a 1:15 ratio prior to performing 
quantitative real-time PCR using SYBR Green PCR Master Mix (Applied 
Biosystems).  
Western Blotting  
 Sorted cells were lysed with radioimmunoprecipitation assay buffer 
(RIPA) consisting of 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and 50 mM Tris (pH 8.0), as 
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well as 2X SDS sample buffer consisting of 1 M Tris (pH 6.8), 50% glycerol, 10% 
SDS, 0.5% bromophenol blue, 0.5% β-mercaptoethanol, 5 μM MG132 proteasome 
inhibitor (EMD Millipore San Diego, CA, USA), and cOmplete EDTA-free 
protease inhibitor cocktail tablets (1 tablet per 10 ml) (Roche Diagnostics, 
Indianapolis, IN, USA).  Cell lysates were fractionated in an 8.5% polyacrylamide 
gel and immunoblotted.  Gels were wet-transferred to PVDF membranes (EMD 
Millipore) using a Bio-Rad transfer apparatus (Bio-Rad Laboratories, Hercules, 
CA, USA).  Membranes were blocked with 5% Blotting Grade Blocker Non-Fat 
Dry Milk (Bio-Rad Laboratories) and primary antibody incubation was 
performed overnight at 4°C using the following primary antibodies: rabbit 
monoclonal RUNX1 (Cell Signaling Technology, Danvers, MA, USA: #4336, 
1:1000); rabbit monoclonal RUNX2 (Cell Signaling Technology #12556, 1:1000); 
rabbit monoclonal Zeb1/TCF8 (Cell Signaling Technology #3396, 1:1000); mouse 
monoclonal Vimentin (Santa-Cruz Biotechnology, Santa Cruz, CA, USA: sc-6260, 
1:1000); mouse monoclonal E-cadherin (Santa Cruz Biotechnology sc21791, 
1:1000); mouse monoclonal β-Actin (Cell Signaling Technology #3700, 1:1000).  
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) were used for 
immunodetection. Blots were developed using Clarity Western ECL Substrate 
(Bio-Rad Laboratories) and subsequently imaged on the Chemidoc XRS+ 




Statistical Analysis  
Tumorsphere formation efficiency assays were repeated at least three 
times.  The differences in mean values among groups were calculated, and TFE is 
expressed as the mean ± SEM.  qRT-PCR analyses were repeated three times.  
GAPDH was used as a control. Relative mRNA levels were analyzed using a 
student's t-test.  P-values less than 0.05 were considered statistically significant 
(*P < 0.05, **P < 0.01, ****P < 0.0001). 
 
Results 
Identification and Isolation of Breast Cancer Stem Cells 
 We set out to determine if we could identify and isolate CD24low/-/CD44+ 
BCSC populations in the MCF10A progression model.  Indeed, our results 
showed that we were able to identify a CD24low/-/CD44+ subpopulation in the 
MCF10AT1 cell line.  Both the BCSC subpopulation and the non-BCSC 
CD24+/CD44+ population were isolated by FACS.  The BCSC fraction 
represented, on average, between 17 – 23% of total live cells gated.  Matched 
isotype controls and single-stained control samples were use to establish gating 
parameters, and the gating strategy was specifically designed to allow for 
maximum separation between the BCSC and non-BCSC populations with respect 
to CD24 expression: one gate was centered around the densest region of the 
CD24low/-/CD44+ subpopulation and the other gate was centered around the 




Figure 4. FACS Gating Strategy for MCF10AT1 CD24low/-/CD44+ BCSC and 
CD24+/CD44+ non-BCSC Populations. 
A distinct CD24low/-/CD44+ BCSC subpopulation was discovered in the 
MCF10AT1 cells.  Gates were used to isolate non-BCSCs from BCSCs.  The BCSC 






MCF10A/AT1/CA1a Mammosphere/Tumorsphere Assay 
 Next, we investigated whether or not all cell lines in this system were 
capable of forming mammospheres and tumorspheres (see Materials and 
Methods).  Briefly, adherent cells were enzymatically detached and single-cell 
suspensions were created.  Cells were seeded at a density of either 1,000 or 2,000 
cells per well in 24-well ultra low-attachments plates and maintained in serum-
free culture medium for a period of five to seven days.  Our results showed that 
MCF10A mammosphere as well as MCF10AT1 and MCF10CA1a tumorsphere 
cultures were successfully established and maintained in culture for a period of 
five days.  Each cell line was cultured in four separate wells in order to have four 
technical replicates.  Photomicrographs were taken every twenty-four hours for 
the duration of culture.  A minimum of four images was taken for each well in 
order to create an archive of the most representative images possible.  MCF10A 
mammospheres measured ≤ 100 μm in size, while MCF10AT1 and MCF10CA1a 
tumorspheres measured between 100 - 400 μm in size.  Tumorspheres showed a 
drastically larger morphology compared to mammospheres.  MCF10AT1 
tumorspheres exhibited a more uneven and rough surface morphology than 
MCF10CA1a tumorspheres, which exhibited a smooth surface morphology 
(Figure 5).  As we expected, due to the fact that cancer cells divide 
uncontrollably, the tumorspheres formed by the cancerous cell lines were 
markedly larger than the mammospheres formed by the MCF10A cells.  The 
unique morphologies associated with the three-dimensional spheroids formed 
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Figure 5. MCF10A, MCF10AT1 and MCF10CA1a Mammosphere/Tumorsphere 
Assays. 
MCF10A (mammosphere), MCF10AT1 and MCF10CA1a (tumorsphere) cultures 
were successfully established and maintained in culture for a period of 5 days.  
Tumorspheres exhibited a larger morphology compared to mammospheres, and 
distinct morphological differences between spheroids from the three different 
cell lines were observed.  Images shown are representative of at least three 










Tumorsphere Forming Capacity of MCF10AT1 Subpopulations 
 In order to gain further insight into the true tumorsphere forming ability 
of BCSCs versus non-BCSCs from MCF10AT1 cell cultures, we performed three-
dimensional tumorsphere assays with FACS-sorted populations.  Tumorsphere 
cultures from CD24low/-/CD44+ BCSCs and CD24+/CD44+ non-BCSCs were 
successfully established and maintained in culture for a period of seven days.  
Photomicrographs were taken every twenty-four hours for the duration of 
culture.  Tumorspheres formed from CD24+/CD44+ non-BCSCs measured ≤ 100 
μm in size, while CD24low/-/CD44+ BCSC tumorspheres measured in excess of 
400 μm in size over the course of seven days (Figure 6).  In these experiments, 
there were extreme size and morphological differences in spheroids formed by 
BCSCs compared to non-BCSCs, and these observations were consistent 
throughout multiple biological replicates. 
 In order to quantify the tumorsphere forming ability of both cancer stem 
cell and non-cancer stem cell populations, we calculated the tumorsphere 
forming efficiency (TFE) of each population.  TFE was compared between 
MCF10AT1 CD24low/-/CD44+ BCSCs and the CD24+/CD44+ non-BCSC 
population. TFE values were as follows: BCSCs = 3.63 ± 0.15% SEM, and non-
BCSCs = 1.4 ± 0.15% SEM (Figure 7).  As expected, the cancer stem cell 
subpopulation had a much higher TFE than the non-stem cell population and the 




Figure 6. MCF10AT1 CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC 
Tumorsphere Assays.  
(A) Tumorspheres formed from FACS-isolated BCSCs exhibited a vastly different 
morphology than those formed from (B) FACS-isolated non-BCSCs. Images 







Figure 7. Analysis of Tumorsphere Forming Efficiency in MCF10AT1 CD24low/-
/CD44+ BCSC and CD24+/CD44+ non-BCSC Tumorsphere Assays.  
MCF10AT1 CD24low/-/CD44+ BCSCs exhibited increased tumorsphere forming 
efficiency (p = 0.0019) compared to the CD24+/CD44+ non-BCSC population. 














RNA and Protein Expression Analysis of MCF10AT1 CD24low/-/CD44+ BCSCs 
vs. CD24+/CD44+ non-BCSCs 
 We next examined expression of several genes, including several stem cell 
markers, in the CD24low/-/CD44+ breast cancer stem cell population of 
MCF10AT1 cells compared to the CD24+/CD44+ non-breast cancer stem cell 
population. The CD24low/-/CD44+ breast cancer stem cell population of 
MCF10AT1 cells exhibited a statistically significant increase in expression of 
RUNX2 (p = 0.0068), Vimentin (p = 0.0026), Nanog (p = 0.0034), Zeb1 (p = 
0.0022), and Zeb1 lncRNA (p = 0.0063) compared to non-BCSCs, and showed a 
statistically significant decrease in expression of RUNX1 (p = 0.041), Oct 4 (p = 
0.013) and CD24 (p < 0.0001) compared to non-BCSCs (Figure 8).  CD44 RNA 
expression was elevated in BCSCs, though this difference was not statistically 
significant (Figure 8).  RUNX1 decreased slightly (p = 0.041) and RUNX2 
increased slightly (p = 0.0068) within the CD24low/-/CD44+ BCSCs compared to 
the non-BCSCs.  The changes in RUNX1 and RUNX2 expression appeared to 
decrease and increase, respectively, with CD24 expression.  The pluripotency 
marker Nanog increased in expression (p = 0.0034) in the BCSC population 
compared to non-BCSCs, and expression of Nanog increased with decreased 
CD24 expression.  Similarly, expression of Zeb1 and Zeb1 lncRNA also increased 
with decreased CD24 expression. 
We observed a reciprocal relationship between RUNX1 and RUNX2 
expression in MCF10AT1 BCSCs.  We know from our observations in the MCF7 
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cell line that knockdown of RUNX1 can increase TFE and promote 
tumorigenicity.  Given our observation that expression of RUNX2 is increased in 
BCSCs, and considering the fact that RUNX2 is involved in metastatic cancer, we 
hypothesized that RUNX2 is involved in promoting or maintaining stemness in 
the BCSC population, and that knockdown of RUNX2 will decrease TFE in the 









Figure 8. Gene Expression Analysis of MCF10AT1 CD24low/-/CD44+ BCSCs vs. 
CD24+/CD44+ non-BCSCs. 
MCF10AT1 BCSCs exhibited significantly increased expression of RUNX2, 
Vimentin, Nanog, Zeb1 and Zeb1 lncRNA compared to non-BCSCs, as well as 
significantly decreased expression of RUNX1, Oct4 and CD24 compared to non-
BCSCs. P-values are shown where expression differences were significant. The 






Consistent with results from RNA expression analysis, MCF10AT1 CD24low/-
/CD44+ BCSCs exhibited a marked increase in RUNX2, Zeb1 and Vimentin 
protein levels, and a decrease in RUNX1, E-Cadherin and CD24 protein levels 
compared to non-BCSCs.  β-actin was used as a loading control.  Western blot 
and protein quantification results are representative of one biological replicate, 
and thus not statistically significant.  However, others in our group have 
replicated these experiments in triplicate and results are consistent with the data 



















Figure 9. Western Blots and Protein Quantification of RUNX1, RUNX2, Zeb1, 
Vimentin and CD24 in MCF10AT1 CD24low/-/CD44+ BCSCs vs. CD24+/CD44+ 
non-BCSCs. 
BCSCs exhibited a marked increase in RUNX2, Zeb1 and Vimentin as well as a 
decrease in RUNX1, E-Cadherin and CD24 compared to non-BCSCs as indicated 











CD24/CD44 Flow Cytometric Analysis and Tumorsphere Forming Efficiency 
of MCF10AT1 shRUNX2 Knockdown Cells 
 In order to test our hypothesis that knockdown of RUNX2 will decrease 
the BCSC population, CD24/CD44 flow cytometry was performed on 
MCF10AT1 parental, shRUNX2 knockdown, and empty vector control cells lines.  
Results show that the distinct CD24low/-/CD44+ BCSC subpopulation observed in 
the parental cells is decreased in shRUNX2 knockdown cells versus empty vector 
control.  According to FACS analysis, the CD24low/-/CD44+ subpopulation 
represents ~ 24% of live-gated cells in the parental cell line, ~ 12% of live-gated 
cells in the EV control, and ~ 4% of live-gated cells in the shRUNX2 cell line.  
These results are representative of three biological replicates (Figure 10). 
 In order to gain further evidence in support of our hypothesis, we 
examined the tumorsphere forming ability of MCF10AT1 shRUNX2 cells, 
shRUNX2 empty vector control, and the MCF10AT1 parental cell line.  The TFE 
of shRUNX2 MCF10AT1 cells was 0.70 ± 0.12% SEM versus 1.53 ± 0.15% SEM for 
the empty vector control and 1.83 ± 0.12% SEM for the parental cell line (Figure 
11). These results support our hypothesis that knockdown of RUNX2 decreases 










Figure 10. CD24/CD44 Flow Cytometry of MCF10AT1 shRUNX2 Knockdown 
Cells vs. Parental and Empty Vector Control. 
MCF10AT1 shRUNX2 knockdown cells showed a marked decrease in the  
CD24low/-/CD44+ BCSC subpopulation vs. empty vector control and parental 
cells. The CD24low/-/CD44+ subpopulation represents ~ 24% of live-gated cells in 
the parental cell line, ~ 12% of live-gated cells in the EV control, and ~ 4% of live-










Figure 11. Tumorsphere Assays and TFE Analysis of MCF10AT1 shRUNX2 
Knockdown Cells vs. Parental and Empty Vector Control. 
MCF10AT1 shRUNX2 knockdown cells exhibited decreased tumorsphere 
forming efficiency compared to empty vector control and parental. Assay was 




 In order to obtain a robust CD24-/CD44+ breast cancer stem cell 
population, we turned to the MCF10A/AT1/CA1a breast cancer progression 
model system [30,31].  Initial flow cytometric analysis revealed a distinct 
CD24low/-/CD44+ BCSC subpopulation within the pre-malignant, tumorigenic 
MCF10AT1 cell line.  This subpopulation exhibited decreased levels of RUNX1 
and increased levels of RUNX2 compared to the non-BCSC population. 
Expression levels of Vimentin, Nanog, Zeb1, and Zeb1 lncRNA were also 
elevated in the BCSC population compared to the non-BCSC population, while 
expression levels of Oct4 and CD24 were decreased in the BCSC population.  We 
also showed that knockdown of RUNX2 decreased tumorigenicity, as measured 
by the tumorsphere formation assay.  Taken together, these observations suggest 
that a combination of low expression of RUNX1 and elevated expression of 
RUNX2 may be involved in the maintenance or development of the breast cancer 
stem cell phenotype. 
 The shRNA RUNX2 knockdown MCF10AT1 cell line was created by 
Alexandra Ojemann, a Master’s student in the Stein-Lian Laboratory.  However, 
subsequent RNA-seq analysis indicated that this may not have been a complete 
knockdown.  As a result, the observations made here cannot be interpreted with 
a high degree of certainty, and it would be appropriate to repeat these 
experiments with a different set of shRUNX2 knockdown cell lines. 
 
45		
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
 The findings presented in this body of research provide evidence that 
regulation of, or cellular pathways involved in the regulation of, RUNX1 and 
RUNX2 may be important for the maintenance of the breast cancer stem cell 
phenotype.  We were able to show, in two different model systems, that low 
expression levels of RUNX1 and elevated expression levels of RUNX2 are 
present in CD24low/-/CD44+ breast cancer stem cells. 
 In Chapter 2, we show definitively that knockdown of RUNX1 enhances 
tumorigenicity in breast cancer cells, as measured by tumorsphere formation 
efficiency.  In Chapter 3, our observations suggest that knockdown of RUNX2 
depletes the CD24low/-/CD44+ breast cancer stem cell subpopulation and 
represses tumorigenicity of breast cancer cells, as measured by the tumorsphere 
formation assay. 
 
Implications and Future Directions 
 The results presented in this thesis represent preliminary investigations 
into the putative roles of RUNX1 and RUNX2 in maintenance of the breast cancer 
stem cell phenotype.  In order to lend more credence to these observations, the 
work with the MCF7 cell line needs to be reproduced and expanded upon, and 
the work done with the knockdown RUNX2 MCF10AT1 cells needs to be 
repeated with newly created stable knockdown cell lines.  There are several 
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exciting implications put forth by this body of work that, if expanded upon, have 
the potential to reveal significant insights into the putative roles of RUNX1 and 
RUNX2 in regulating the breast cancer stem cell phenotype.  This body of work 
has, for the first time, effectively established three-dimensional cancer stem cell 
culture protocols for our group.  There is no doubt that, with time, our group 
will expand upon these studies in order to glean further insights into the 
mechanisms that govern stemness in breast cancer.   
 Using the mammosphere/ tumorsphere culture protocols for a variety of 
breast cancer cell lines that have been developed through this work, there are 
several avenues of investigation that we can now potentially pursue.  It would be 
very exciting to see if we can establish tumorsphere cultures from patient breast 
cancer tissue samples, isolate and conduct analyses on the CD24low/-/CD44+ 
fraction, and compare the results to those obtained through these investigations.  
A study such as this would enable us to gain further insight into the involvement 
of RUNX1 and RUNX2 in regulating or maintaining the BCSC phenotype.  
Furthermore, we now have a three-dimensional cell culture system designed to 
enrich for BCSCs that can potentially be used for drug screening, toxicity testing, 
and further knockdown experiments.   
 Given the fact that traditional cancer therapeutics are insufficient at 
targeting breast cancer cells with stem cell-like properties, it is of paramount 
importance that genes and regulatory molecules responsible for governing 
stemness in breast cancer cells are identified so that novel therapies can be 
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developed to target and eliminate this incredibly dangerous subpopulation of 
cells.  Indeed, it is widely accepted that breast cancer stem cells are a main 
causative factor in the initial onset of cancer, and are thought to be responsible 
for cancer recurrence following remission, as well as metastasis that ultimately 
leads to death.  Findings from this research lay a strong groundwork for future 
investigations into cellular pathways that govern stemness in breast cancer cells.  
Gene expression analyses performed here provide interesting starting points for 
future investigation into genes that are potentially involved in maintaining the 
breast cancer stem cell phenotype.  It would also be very interesting to analyze 
these BCSC populations at the epigenetic level in order to gain insight into 
epigenetic regulatory mechanisms involved in governing the breast cancer stem 
cell phenotype.  
 Since there still remains much debate over the consensus of population-
defining cell-surface markers, and taking into consideration the fact that there is 
a general lack of cell-surface markers ascribed to them, it continues to be 
extremely challenging to identify and isolate cancer stem cells (CSCs) from solid 
tumors.  As a result, functional assays are the techniques that are predominantly 
used to assess the ability of CSCs, or prospective CSC populations, to generate 
tumors via self-renewal, asymmetric division, and differentiation.  Many of these 
assays are extremely costly and time-consuming because they are based on the 
formation of tumors in vivo following xenograft transplantations into 
immunocompromised mice.  Since the capability to form spheroids in vitro is an 
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established method to identify CSC populations, spheroid formation assays 
represent a relatively low-cost in vitro model with which to investigate the CSC 
phenotype.   
 Three-dimensional cell culture systems are thought to better mimic the in 
vivo cancer environment compared to traditional two-dimensional monolayer 
systems.  Some of the most popular three-dimensional cell culture systems for 
studying breast cancer are tumorspheres and organoids, and tumorsphere 
culture is specifically known to enrich for BCSCs.  Future investigations in the 
field utilizing these two systems will surely help to usher in the discovery of yet 
to be identified cell-surface markers that will ultimately aid in the development 
of therapeutics that can target the dangerous BCSC cell populations with 
enhanced specificity [52-54].  In fact, several developments have occurred since 
the writing of this manuscript that have served to advance the fields of breast 
tumorsphere and organoid research.  Dr. Hans Clever’s Laboratory has 
developed a breast cancer organoid biobank consisting of over one hundred 
organoid lines.  Since these organoids are by definition patient-derived three-
dimensional cell culture systems, they are highly representative of their in vitro 
breast tumor counterparts, and these models have been adapted for high-
throughput screening [55].  The Clevers Lab has also developed organoid 
systems for gastrointestinal cancers, which they’ve shown to be highly effective 
models for drug screening.  In these patient-derived gastrointestinal organoid 
cultures, every time that a drug did not work in a patient’s organoids, it also did 
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not work in the patient.  Furthermore, in almost nine out ten cases when drugs 
were first tested and shown to work in a patient’s organoids, the patient 
exhibited a response to the drug [56].  Tumorspheres differ from organoids in 
that they don’t recapitulate the original tissue hierarchy to the same extent, 
however they are three-dimensional cell culture systems that better mimic the in 
vivo environment than traditional two-dimensional monolayer systems, they are 
more cost effective and less time-consuming, and tumorsphere cultures can also 
be readily adapted for high-throughput screening.   
 It is clear that three-dimensional cell culture systems will play an 
incredibly important role in the future of cancer research.  The protocols 
established via this body of research have laid the groundwork for our group to 
further investigate the molecular mechanisms of breast cancer progression and 
metastasis using three-dimensional tumorsphere culture.  This body of work has 
also provided invaluable insights into the involvement of RUNX1 and RUNX2 in 
the maintenance of the BCSC phenotype; insights that can be expanded upon to 
further our understanding of BCSC biology, aid in the discovery of novel BCSC 
markers, and assist in investigations into the mechanisms of epigenetic 
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